Brain scans show that psilocybin modulates claustrum connectivity in brain networks.
Results support the idea that serotonin 5-HT2A receptor-directed therapeutic strategies may be superior to ketamine-based treatments for depression.
A study from McGill University shows that the power of the mind alone can produce a quasi-psychedelic experience.
Recent research suggests that psilocybin causes changes in amygdala activity opposite to those seen in conventional antidepressant treatment.
UK Health Technology Assessment body raises questions over the clinical and cost-effectiveness of Spravato (esketamine).
New research suggests that ketamine can aid in reorganizing alcohol-related memories.
A recent Nature paper provides novel insights into the neural correlates of the Breakthrough Experience associated with DMT.
A look into the promising potential of artificial intelligence in tackling unmet medical needs in mental healthcare
A look into the less discussed therapeutic aspect of psychedelics: the anti-inflammatory effect.
Market introduction of psychedelics as a therapy looks promising. However, policy and regulatory issues concerning the drug class still exist.